

Tildrakizumab-asmn (Ilumya & Biosimilars) Injection Order Form**Patient Name:** _____**Date of Birth:** _____**Patient Phone #:** _____**Date:** _____**Therapy Status:** ☐ New Start ☐ Continuation ☐ Restart**Last Dose:** _____

Height (inches)	Weight (kg)	Allergies

Diagnosis

ICD-10 Code(s): _____

J Code(s): _____

Labs (Recommended to be done within 30 days of first dose)

- ☐ Labs to be reviewed or ordered by infusion center
- ☒ Baseline
 - ☒ TB screening (QuantIFERON or alternative)
 - ☐ Maintenance (every year)
 - ☐ TB screening (QuantIFERON or alternative)
- ☐ Labs reviewed by ordering provider, ok to proceed (Labs last done on _____)
- ☐ Other: _____ ☐

Nursing Order

- ☒ Do not administer Tildrakizumab with an active infection, including clinically important localized infection, or if patient is taking antibiotics for current infection.
- ☒ Pregnancy status: If uncertain, obtain HCG urine test for women 11 – 50 years prior to treatment.

Pre-Medications (Not routinely recommended, use only if clinically indicated)

- | | |
|--|--|
| ☐ Acetaminophen 650 mg PO once | ☐ Dexamethasone 20 mg IV once |
| ☐ Diphenhydramine 25 mg PO once | ☐ Dexamethasone 20 mg PO once |
| ☐ Diphenhydramine 25 mg IV once | ☐ Methylprednisolone 125 mg IV once |
| ☐ Diphenhydramine 50 mg PO once | ☐ Methylprednisolone 40 mg IV once |
| ☐ Diphenhydramine 50 mg IV once | ☐ Other: _____ |
| ☐ Famotidine 20 mg IV once | |
| ☐ Famotidine 20 mg PO once | |

Tildrakizumab-asmn (Ilumya & Biosimilars) Injection Order Form

Medication Orders (select loading & maintenance dose)

Loading Dose

☐ Tildrakizumab 100 mg SQ once at weeks 0 and 4

Maintenance Dose

☐ Tildrakizumab 100 mg SQ once every 12 weeks

Refills:

(Refills for one year from date of signature unless indicated)

☐ Zero ☐ For 12 months ☐ _____

To be completed by Infusion Center staff only:

Biosimilar substitution/Product Dispensed: _____ J-Code: _____
Rounded Dose: _____ mg

Rationale for Substitution:

- ☐ Payer-mandated substitution
☐ Financial stewardship
☐ Patient access / hardship

Pharmacy may substitute a biosimilar based on insurance coverage.

Pharmacy may adjust diluent, volume, and infusion duration in accordance with local practice standards.

Administration Instructions

Administer subcutaneously in the abdomen, thigh or upper arm

Infusion Center Staff

Please fax infusion records or discharge summary to: Fax Number _____

Provider Information

Provider Signature: _____ Date: _____

Provider Printed Name: _____ Provider NPI: _____

Provider Address: _____ Phone: _____ Fax: _____

All orders are valid for 1 year from the ordered date unless otherwise indicated